Roger Adsett, Shire
S
Roger Adsett
VP and General Manager, Gastroenterology, Shire
NOTED FOR: Strong leadership, building blockbuster brands
VISION: "Explain it so others internalize—not recite—it"
Roger Adsett knows big brands. He cut his teeth at Astra Merck, heading up marketing for Nexium, then moved to England to serve as global brand director for AstraZenica's Symbicort. Now re-settled in the Northeast corridor, he's translating marketing savvy and global know-how to Shire's GI business—with good results. Last year's launch of Lialda sent business soaring, without cannibalizing Pentasa sales. Shire brands now serve more than a quarter of the oral mesalamine market. And with a co-promotion deal signed with TAP, Adsett will bring his blockbuster mindset to the realm of specialty sales.
Roger Adsett
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
